Baseline characteristics, study treatments, and response
| Baseline characteristics . | Study treatment and response . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ID . | Sex/Race . | Age at study entry, y . | Concurrent KS/(Stage) . | Time from HIV Dx, mo . | Time from MCD Dx, mo . | Prior therapy for KSHV-MCD or KS . | No. of Tx cycles . | Best response on TCZ alone . | Addition of AZT/ VGC* . | Best response on TCZ +AZT/ VGC . | Response at EOT . | Subsequent therapy . | Time to next therapy, mo . |
| 1 | M/Black | 50 | N | 189 | 107 | Rituximab monotherapy | 6 | PR | Y from C4 | PR | PR | Rituximab | 4 |
| Rituximab/LD | |||||||||||||
| 2 | M/Asian | 47 | N | 51 | 4 | Paclitaxel | 5 | PR | Y from C4 | PR | PD | Rituximab/ LD | 2 |
| 3 | M/Black | 28 | N | 25 | 2 | None | 6 | PD | Y from C2 | CR | CR | Rituximab/ LD | 8 |
| 4 | F/Black | 30 | N | 2 | 1 | Prednisone | 6 | CR | N | — | CR | None | — |
| 5 | M/White | 63 | Y/(T1I0S1) | 108 | 52 | Rituximab, vinorelbine, rituximab/LD, carfilzomib, sirolimus, LD | 6 | PR | N | — | PR | Pom/LD | 4 |
| 6 | M/White | 42 | Y/(T1I1S1) | 5 | 1 | None | 2 | PR | N | — | PD | Pom/LD | 1 |
| 7 | M/White | 64 | N | 206 | 18 | Rituximab | 6 | SD | N | — | PD | Rituximab | 3 |
| 8 | M/Black | 54 | N | 279 | 12 | None | 2 | SD | N | — | PD | Rituximab | 1 |
| 49† | — | 79† | 8† | — | 6† | — | — | — | — | — | 3† | ||
| Baseline characteristics . | Study treatment and response . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ID . | Sex/Race . | Age at study entry, y . | Concurrent KS/(Stage) . | Time from HIV Dx, mo . | Time from MCD Dx, mo . | Prior therapy for KSHV-MCD or KS . | No. of Tx cycles . | Best response on TCZ alone . | Addition of AZT/ VGC* . | Best response on TCZ +AZT/ VGC . | Response at EOT . | Subsequent therapy . | Time to next therapy, mo . |
| 1 | M/Black | 50 | N | 189 | 107 | Rituximab monotherapy | 6 | PR | Y from C4 | PR | PR | Rituximab | 4 |
| Rituximab/LD | |||||||||||||
| 2 | M/Asian | 47 | N | 51 | 4 | Paclitaxel | 5 | PR | Y from C4 | PR | PD | Rituximab/ LD | 2 |
| 3 | M/Black | 28 | N | 25 | 2 | None | 6 | PD | Y from C2 | CR | CR | Rituximab/ LD | 8 |
| 4 | F/Black | 30 | N | 2 | 1 | Prednisone | 6 | CR | N | — | CR | None | — |
| 5 | M/White | 63 | Y/(T1I0S1) | 108 | 52 | Rituximab, vinorelbine, rituximab/LD, carfilzomib, sirolimus, LD | 6 | PR | N | — | PR | Pom/LD | 4 |
| 6 | M/White | 42 | Y/(T1I1S1) | 5 | 1 | None | 2 | PR | N | — | PD | Pom/LD | 1 |
| 7 | M/White | 64 | N | 206 | 18 | Rituximab | 6 | SD | N | — | PD | Rituximab | 3 |
| 8 | M/Black | 54 | N | 279 | 12 | None | 2 | SD | N | — | PD | Rituximab | 1 |
| 49† | — | 79† | 8† | — | 6† | — | — | — | — | — | 3† | ||
—, not applicable; C2, cycle 2; C4, cycle 4; Dx, diagnosis; EOT, end of treatment; F, female; ID, identification number; LD, liposomal doxorubicin; M, male; mo, months; N, No; PD, progressive disease; Pom, pomalidomide; SD, stable disease; TCZ, tocilizumab; Tx, treatment; Y, yes; y, years.
C4 and C2 denote cycle when AZT/VGC started.
Median.